Cerus Co. (NASDAQ:CERS) has earned an average rating of “Hold” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $6.50.
A number of brokerages recently issued reports on CERS. Cantor Fitzgerald set a $5.00 price objective on Cerus and gave the company a “buy” rating in a research note on Monday, January 8th. BidaskClub upgraded Cerus from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. ValuEngine upgraded Cerus from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Zacks Investment Research downgraded Cerus from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, BTIG Research restated a “neutral” rating on shares of Cerus in a research note on Friday, December 8th.
A number of hedge funds have recently bought and sold shares of CERS. BB&T Securities LLC bought a new position in Cerus in the 3rd quarter worth approximately $100,000. UBS Asset Management Americas Inc. boosted its stake in Cerus by 59.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 18,000 shares during the period. Voya Investment Management LLC boosted its stake in Cerus by 22.0% in the 2nd quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 10,570 shares during the period. Turner Investments LLC bought a new position in Cerus in the 3rd quarter worth approximately $177,000. Finally, Ardsley Advisory Partners bought a new position in Cerus in the 2nd quarter worth approximately $200,000. Institutional investors and hedge funds own 55.72% of the company’s stock.
Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. The company had revenue of $10.80 million during the quarter, compared to the consensus estimate of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.14) EPS. research analysts predict that Cerus will post -0.57 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Cerus Co. (CERS) Given Average Rating of “Hold” by Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/19/cerus-co-cers-given-average-rating-of-hold-by-brokerages.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.